Brian Nowosielski

Tom Kraus, JD, of ASHP, and Shawn Gremminger, MPP, of the National Alliance of Healthcare Purchaser Coalitions, face off on the 340B Drug Pricing Program.

In part 2, Blank argues that the language on a medication’s label deserves the same regulatory scrutiny given to the drugs themselves and how they affect patients.

Researchers explore prenatal alcohol use among expectant mothers in the US spanning 2011 to 2024.

Study findings underscore health care’s gradual push into the technologically driven future of health care, leaving in-store destinations behind.

Managing diabetes has shifted from reactive monitoring to a proactive, technology-driven standard of care that emphasizes real-time data and personalized treatment.

Sharon Blank, CEO of RxTran and Language Scientific, discusses language hurdles in the safe delivery of medications for patients and pharmacists alike.

Researchers design, implement, and evaluate the use of social determinants of health screening and referral services within Medicaid payer programs.

Pharmacists were asked about their perceived knowledge and attitudes toward patients with Down syndrome.

In the first of a 2-day hearing on peptide therapy access, the FDA votes in favor of approving 4 of the products discussed, with the potential for more on Friday.

Experts collaborate on the best approaches for boosting immunization rates in populations across school campuses and shared living facilities.

As the pharmacist’s role continues to expand throughout health care, they are now being challenged to step in as opioid stewards in a rapidly evolving pain management landscape.

Through pharmacists’ statewide billing capabilities, researchers explore how educational support impacts community pharmacies’ medical billing.

Through the lens of pharmacist satisfaction, researchers assess the implementation and real-world use of medication alert systems.

In part 2, Richard Dion, PharmD, addresses some of the persistent challenges among hospital pharmacies and their pain management models, offering some expert solutions to move forward.

This episode explores PBMs’ copay collection discrepancies and how improper documentation can be the downfall for pharmacy business.

Immunology expert Paul Licciardi, PhD, weighs in on the current state of recommended pneumococcal vaccines and what is on the horizon in the developmental stage.

In part 2, Paul Licciardi, PhD, dives into the evolving need for updated pneumococcal vaccine recommendations and how pharmacists can keep their patients informed.

Richard Dion, PharmD, joins to discuss the growing prominence of opioid stewardship and where the pharmacist can assist in patient programming.

Analyzing nearly a decade of pharmaceutical interventions in community pharmacies, researchers reveal the role pharmacists play in self-medication.

In part 1 of our interview with Paul Licciardi, PhD, he addresses the lowered pneumococcal vaccination age as well as the adult population’s overall relationship with immunization.

With calls to expand access across the health care ecosystem, researchers explore pharmacists' perceptions regarding independent prescribing.

With the Medicare GLP-1 Bridge Program just 2 weeks old, a drug market expert shared their thoughts on what the initiative may mean for pharmacists and their patients.

Among adult patients who have reported a case of invasive pneumococcal disease, researchers address the association of risk factors and recurrent disease.

In this episode, Natalie DiPietro Mager, PharmD, PhD, talks with Mark Garofoli, PharmD, MBA, BCGP, CPE, CTTS, about how pharmacists can address cannabis use in women during adolescence, reproductive years, and older adulthood.

With GLP-1 questions creating confusion for Medicare patients, pharmacists are becoming the trusted frontline resource, and the stakes for getting it right have never been higher.

With the goal of optimizing long-term weight-loss treatment, researchers gather insights regarding the lived experiences of glucagon-like peptide-1 users.

In an assessment of pharmacy closures, researchers hypothesize underserved neighborhoods would be the most burdened locations across the country.

This episode meanders the time of the year where pharmacy professionals experience a lull in business, providing them with the perfect opportunity to invest in growth.

Jay Bregman, founder and CEO of Andel, discusses the current GLP-1 landscape and how a new Medicare initiative is designed to improve access to this increasingly popular medication class.

Researchers assess how these emerging platforms can support medication use across this patient population.